1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On September 23, 2026, Greenland Mines agreed to sell 1,765,420 common shares and pre-funded warrants for up to 1,434,580 shares to institutional investors at $12.00 per share or warrant, for a total of up to 3,200,000 shares. Net proceeds are expected to be about $38.4 million, to be used with existing cash for Greenland mining operations, general corporate uses and working capital, with closing expected on or about September 24, 2026. The sale adds new shares that will dilute existing holders.
Offering of 1,765,420 common shares plus pre-funded warrants for up to 1,434,580 shares, priced at $12.00 each
Expected net proceeds of about $38.4 million, after estimated offering expenses
Expected closing on or about September 24, 2026, subject to customary conditions
On September 21, 2026, private warrants were amended to a post-reverse-split exercise price of $5.00 per share
IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings, completed a $2 billion offering of 6.375% senior notes maturing March 15, 2034. Proceeds will redeem the issuer's 5.000% notes due 2026, repay part of its revolving credit facility and cover offering fees. The deal refinances existing debt and adds new long-term borrowing, which shareholders may weigh against the company's debt load.
Gross proceeds of $2,000,000,000 from 6.375% senior unsecured notes due March 15, 2034
Proceeds to redeem in full the Senior 5.000% Notes due 2026 and repay part of the revolving credit facility
Interest payable semi-annually on March 15 and September 15, starting March 15, 2027
Issuer may redeem before September 15, 2029 subject to a make-whole premium
Decoy Therapeutics reduced the exercise price of its Series B milestone warrants from $5.91 to $3.25 per share, and the holder exercised 1,184,434 of them in full, bringing approximately $3.85 million in gross proceeds before placement agent fees and expenses; the transaction closed September 23, 2026. In exchange, the company issued new unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately and expiring five years after issuance, which could add meaningful share count dilution for existing holders.
1,184,434 Series B Milestone Warrants exercised in full on September 22, 2026 at a reduced price of $3.25, down from $5.91 per share.
Gross proceeds of approximately $3.85 million, before placement agent fees and other expenses, to be used for working capital and general corporate purposes.
New unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately, expiring five years from issuance.
The company agreed to file a resale registration statement within 15 calendar days of the September 22, 2026 inducement letter.
QuidelOrtho entered into Amendment No. 1 to its credit agreement dated August 21, 2025, with Bank of America as administrative agent. The amendment resets the maximum leverage and minimum interest coverage covenant levels through the fiscal quarter ending September 30, 2029, and sets new pricing and commitment fees during that period. The filing describes added restrictions on the financial covenants, so shareholders gain covenant room but face tighter terms in the interim.
Amendment dated September 23, 2026 to the credit agreement originally dated August 21, 2025
Maximum Consolidated Leverage Ratio set at 5.50 to 1.00 for quarters through July 2, 2028, stepping down to 4.25 to 1.00 on or after September 30, 2029
Minimum Consolidated Interest Coverage Ratio set at 2.25 to 1.00, rising to 3.00 to 1.00 on or after September 30, 2029
Initial Term SOFR margin of 2.50% per annum for the Term Loan A facilities and revolver until the compliance certificate for the quarter ending September 28, 2026 is received; term loan B interest unchanged
Flotek Industries entered into a Credit Agreement on September 23, 2026, with initial term loans of $75.0 million, secured by substantially all company and subsidiary guarantor assets. The loan refinanced the $40 million PWRTEK Note, which had been guaranteed by Flotek, and matures September 23, 2031. Part of the lender group is an affiliate of ProFrac's founders, a related party, and the Audit Committee approved the transaction.
Initial term loans of $75.0 million, with up to $15.0 million more delayed-draw available through June 30, 2027 and up to $30.0 million more subject to Required Lender consent through March 31, 2028
Interest at Term SOFR with a 2.50% floor plus a 6.50% margin; maturity September 23, 2031
PC Energy Credit I LLC, an affiliate of ProFrac's founders, exchanged $12.5 million of PWRTEK Note obligations for initial term loans
Asset-based loan with Amerisource extended to October 31, 2027, with the PWRTEK Note terminated and its liens released
Alcoa's subsidiaries completed a $2.6 billion private sale of senior notes due 2034 and 2036, with proceeds and cash on hand intended to fund the approximately $3.1 billion cash portion of the proposed South32 bauxite, alumina and aluminum smelter acquisition. The notes must be redeemed at 100% of principal plus accrued interest if the acquisition is not completed by the Special Mandatory Redemption End Date, which is at least June 29, 2027, and the company terminated its 364-day bridge loan commitments for the deal.
$1.5 billion of 6.625% senior notes due 2034 issued by Alumina Pty Ltd and $1.1 billion of 6.875% senior notes due 2036 issued by Alcoa Nederland Holding B.V.
Proceeds plus cash on hand are intended to fund the approximately $3.1 billion cash portion of the South32 acquisition and related fees and expenses.
If the acquisition is not completed by June 29, 2027, or a later date under the Deed, the notes must be redeemed at 100% of principal plus accrued interest.
Concurrently with the notes closing, Alcoa terminated all remaining commitments under its 364-day senior unsecured bridge term loan facility.
Range Capital Acquisition Corp. disclosed that on September 22, 2026, it drew $60,000 from an unsecured, non-interest-bearing promissory note issued to its sponsor and deposited the funds into its trust account. Total outstanding under the note is now $240,000, and the note is repayable only on completion of an initial business combination or the effective winding up of the company, with repayment outside the trust if no combination occurs.
Drawdown of $60,000 on September 22, 2026, deposited into the Trust Account
Aggregate outstanding balance under the note is $240,000
Note issued June 18, 2026, up to $540,000 principal, to sponsor Range Capital Acquisition Sponsor, LLC
Note is non-interest-bearing; sponsor contributions of up to $60,000 per month
FMC closed the sale of 30,319,166 common shares to Tessenderlo Group NV at $13.30 per share, for an aggregate purchase price of $403,244,907.80, on September 23, 2026. Tessenderlo now owns approximately 20.0% of FMC's outstanding shares and gains a board nomination right, a board observer seat and preemptive rights. The filing also sets a 36-month lock-up and standstill limits, which shape how much influence and share-count dilution existing shareholders may face.
Tessenderlo bought 30,319,166 shares at $13.30 per share, for $403,244,907.80 in total.
Tessenderlo owns approximately 20.0% of FMC's outstanding common stock after the closing.
The Investor Agreement lets Tessenderlo nominate an independent director; Luc Tack, Tessenderlo's chief executive, has been nominated.
Tessenderlo is subject to a 36-month lock-up and customary standstill restrictions while it holds FMC shares.
Teamshares closed the sale of 225,000 shares of a new non-voting, non-convertible Series A Preferred Stock on September 23, 2026, at $990 per share, for an aggregate $222.75 million. The buyers are affiliates of a holder of more than 10% of the common stock, and the company says the proceeds are primarily intended to fund acquisitions. The preferred ranks ahead of common stock on dividends and liquidation, carries a 16.0% cash dividend rate, and includes covenants that restrict debt and require at least $150 million of unrestricted cash until the existing credit facility is refinanced or repaid.
225,000 Series A shares sold at $990 per share, or $222.75 million in aggregate, closed September 23, 2026
Liquidation preference of $1,000 per share; cumulative dividends of 16.0% per year if paid in cash or 18.0% if paid in kind
Ranks senior to common stock; non-voting and not convertible into common stock
Company may sell up to $75 million more of the same series; must keep at least $150 million of unrestricted cash until the existing credit facility is refinanced or repaid
Solaris Energy Infrastructure's subsidiary agreed on September 22, 2026 to sell $1.25 billion of 7.000% senior notes maturing April 1, 2032, in a private placement to initial purchasers led by MUFG Securities Americas. The offering was upsized from an original $1.0 billion, and the company expects about $1,227.2 million in net proceeds for general corporate purposes, growth capital expenditures and offering fees, with closing expected October 1, 2026.
Principal amount: $1.25 billion of 7.000% senior notes due April 1, 2032, issued at par, upsized from $1.0 billion
Expected net proceeds: approximately $1,227.2 million after the initial purchasers' discount and estimated offering expenses
Expected closing: October 1, 2026, subject to customary closing conditions
Use of proceeds: general corporate purposes, growth capital expenditures and offering fees and expenses
Jazz Pharmaceuticals' subsidiary Jazz Financing Lux entered into Amendment No. 4 to its credit agreement on September 23, 2026, extending the maturity of the $1.9 billion Tranche B-2 dollar term loan from May 5, 2028 to May 5, 2033 and lowering its interest margin. The filing does not include new earnings, guidance, or changes to operations, so the effect on shareholders depends on the lower borrowing cost and longer repayment schedule.
Maturity extended from May 5, 2028 to May 5, 2033 for the Tranche B-3 dollar term loans
Applicable margin cut 50 basis points to 1.75% for Term SOFR borrowings and 0.75% for prime rate borrowings, with a 0.50% Term SOFR floor
Principal outstanding of $1,895,000,000 before and after the amendment; Jazz Lux also borrowed $273,310,355.18 in additional term loans to repay non-converted loans
Quarterly amortization of 0.25% of initial principal, with the remaining balance due May 5, 2033
Covista Inc. entered into Amendment No. 6 to its credit agreement on September 18, 2026, repricing all $510 million of outstanding term loans. The Term SOFR margin falls from 2.25% to 2.00%, and the base rate margin falls from 1.25% to 1.00%, which lowers the interest rate on the loans. The filing states that the other terms of the credit agreement were not materially changed.
Amendment No. 6, dated September 18, 2026, repriced all $510 million of term loans, with Morgan Stanley Senior Funding, Inc. as administrative agent.
Term SOFR margin reduced from 2.25% to 2.00%; base rate margin reduced from 1.25% to 1.00%.
A 1.00% soft call applies to certain repricings or prepayments occurring within six months after the September 18, 2026 effective date.
Other material terms are unchanged; the full amended agreement is filed as Exhibit 10.1.
Mobile Infrastructure Corporation signed a Fifth Amendment to its Credit Agreement on September 22, 2026, with Harvest Small Cap Partners entities, extending the maturity date from September 30, 2026 to December 31, 2026. The filing describes the amendment as a related party transaction because co-chair Jeffrey Osher is managing member of the lenders' investment manager; the filing does not state the loan amount. The same day, the board declared monthly preferred stock dividends payable on or about October 12, 2026.
Credit Agreement maturity extended from September 30, 2026 to December 31, 2026 under the Fifth Amendment dated September 22, 2026.
Lenders are Harvest Small Cap Partners, L.P. and Harvest Small Cap Partners Master, Ltd.; co-chair Jeffrey Osher is managing member of No Street Capital LLC, their investment manager.
Series A Preferred Stock dividend of $4.791 per share and Series 1 Preferred Stock dividend of $4.583 per share, payable on or about October 12, 2026.
Record dates: September 27, 2026 for Series A Preferred Stock and September 24, 2026 for Series 1 Preferred Stock.
Pilgrim's Pride Corporation and its subsidiary Pilgrim's Europe Finance PLC completed a private sale of €500 million of 4.750% senior notes due January 23, 2034, on September 23, 2026. The company said it will use the net proceeds for general corporate purposes, including the consideration for its recently announced acquisition of Walkers Deli & Sausage Company, which adds debt that shareholders should weigh against the deal.
Principal amount: €500 million of 4.750% senior notes, issued by Pilgrim's Pride and Pilgrim's Europe Finance PLC as co-issuers
Interest is payable annually in arrears each January 23, starting January 23, 2027; notes mature January 23, 2034
Proceeds are intended for general corporate purposes, including funding the Walkers Acquisition consideration and related costs
Notes were sold to qualified institutional buyers under Rule 144A and to certain non-US persons under Regulation S; Citibank, N.A., London Branch is trustee
Patriot National Bancorp agreed on September 18, 2026 to issue and sell $10.0 million of subordinated notes to qualified institutional buyers. The company says the notes are intended to qualify as Tier 2 regulatory capital, and the filing does not say how the proceeds will be used.
Principal amount: $10.0 million of 8.5% Fixed to Floating Rate Subordinated Notes due 2036, maturing September 30, 2036
Fixed 8.5% annual rate, paid semi-annually until September 30, 2031; afterward resets quarterly to three-month SOFR plus 416 basis points
Company may redeem on or after September 30, 2031, or earlier in certain events, subject to regulatory approval where required
Notes are unsecured, junior to senior indebtedness, not convertible, and not guaranteed by subsidiaries; placement agent was Performance Trust Capital Partners, LLC
Holley made a voluntary $10 million prepayment of principal on its first lien term loan facility on September 22, 2026, and announced it in a press release on September 23. The company says total debt repayments since September 2023 reach $125 million, funded entirely by free cash flow, and that it remains on track for year-end leverage below 3.5x.
Voluntary prepayment of $10 million on first lien term loan made September 22, 2026
Total debt repaid since September 2023 is $125 million, funded by free cash flow
Total Leverage Ratio reduced from a peak of 5.67x; year-end target below 3.5x and long-term target of approximately 3.0x
Cumulative debt reductions generate approximately $5 million in annualized net interest savings
Beyond Meat entered into privately negotiated exchange agreements to swap about $15.0 million of its 0% convertible notes due 2027 for common stock at 96% of face value. The company will issue 1,097,444 shares initially, with a possible additional true-up of up to 848,265 shares, which would dilute existing shareholders.
About $15.0 million principal of 2027 convertible notes to be exchanged at 96% of face value.
Initial settlement of 1,097,444 shares on or about September 23, 2026.
Final true-up settlement, if any, on or about September 28, 2026, for up to 848,265 additional shares.
Share count depends on a VWAP calculation over three trading days starting September 23, 2026, with a $7.4009 floor price.
Armata Pharmaceuticals said it received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 program for AP-SA02, its lead clinical candidate. The company said this is the first DoW funding specifically for Phase 3 execution, and it lifts cumulative non-dilutive DoW support for the program to approximately $32.4 million, which may reduce the need to raise capital through share sales.
Armata received $3.7 million in additional non-dilutive funds from the U.S. Department of War, announced September 23, 2026.
The award is administered through the Medical Technology Enterprise Consortium and funded by the Defense Health Agency and Joint Warfighter Medical Research Program.
Cumulative non-dilutive DoW funding under the award is approximately $32.4 million, following $28.7 million previously provided.
The company plans to start a Phase 3 superiority study of AP-SA02 in complicated S. aureus bacteremia in the second half of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.